On November 6, 2025 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer reported it will present a poster on its proprietary VacDesignR computational tool at the upcoming ESMO (Free ESMO Whitepaper) AI & Digital Oncology 2025 conference, held in Berlin, Germany, from 12-14 November 2025.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will highlight how VacDesignR streamlines the design and production of recombinant Modified Vaccinia Ankara (MVA)-based vectors, enabling faster and more reliable manufacturing of individualized neoantigen therapeutic vaccines (INTV).
The individualized immunotherapies developed through the myvac platform, currently being evaluated in a Phase I/II clinical trial (NCT04183166), are based on an MVA viral vector and their design already leverages the VacDesignR tool.
Developed in-house, VacDesignR is a computational design engine that optimizes recombinant plasmid architecture for MVA vectors, a core component of Transgene’s myvac platform. By minimizing unwanted homologous recombination and intelligently selecting peptide sequences for cassette assembly, VacDesignR significantly improves production reliability and vector quality.
Future iterations of VacDesignR will incorporate AI-based components to further improve performance and scalability, supporting Transgene’s strategy to accelerate production timelines for individualized therapeutic vaccines, including its lead candidate TG4050 designed to treat HPV-negative head and neck cancers following surgery and adjuvant therapy.
"Participating at the first edition of the ESMO (Free ESMO Whitepaper) AI & Digital Oncology meeting highlights Transgene’s pioneering role in combining viral vector-based individualized cancer vaccines with its vaccine design tool to optimize product performance and redefine the future of oncology treatment", commented Maurizio Ceppi, Chief Scientific Officer of Transgene.
Title of the abstract: "VacDesignR: a computational tool to optimize viral-based individualized neoantigen therapeutic vaccine production"
Title of the poster: "VacDesignR: a tool for optimizing recombinant poxvirus vaccine production"
Poster and Abstract number: 385P
Session: Drug development
Date: November 12, 2025
Author: B. Grellier
The poster presentation will take place on November 12 at ESMO (Free ESMO Whitepaper)-AI conference and will be available that day on Transgene’s website.
VacDesignR is a computer-assisted method protected through patent and patent applications derived from WO2021/130210.
(Press release, Transgene, NOV 6, 2025, View Source [SID1234659484])